ALLIE THOMAS-FANNIN: Open Payments
NPI 1942566708 · VINCENNES, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$542 in 38 payments from 11 companies in 2025. Trend: 2023 $258 · 2024 $443 · 2025 $542
Food & beverage: $542
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 18 | $149 |
| Vanda Pharmaceuticals Inc. | 4 | $77 |
| Teva Pharmaceuticals USA, Inc. | 3 | $61 |
| Axsome Therapeutics, Inc. | 2 | $58 |
| Neurocrine BioSciences, Inc. | 2 | $38 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Alkermes, Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Indivior Inc. | 1 | $20 |
Products named: INVEGA SUSTENNA, FANAPT, Auvelity, AUSTEDO XR, INGREZZA, CAPLYTA, ARISTADA, TRINTELLIX.
Industry payments across IN — which companies pay providers there.
